Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography

  • Bioorg Med Chem. 2014 Mar 1;22(5):1700-7. doi: 10.1016/j.bmc.2014.01.019.
Dong Zhou  1 ,  Wenhua Chu  1 ,  Jinbin Xu  1 ,  Lynne A Jones  1 ,  Xin Peng  1 ,  Shihong Li  1 ,  Delphine L Chen  1 ,  Robert H Mach  2
Affiliations
  • 1. Department of Radiology, School of Medicine, Washington University in Saint Louis, St. Louis, MO 63110, USA.
  • 2. Department of Radiology, School of Medicine, Washington University in Saint Louis, St. Louis, MO 63110, USA. Electronic address: [email protected].
PMID: 24503274 DOI: 10.1016/j.bmc.2014.01.019
Abstract

Imaging of poly (ADP-ribose) polymerase-1 (PARP-1) expression in vivo is a potentially powerful tool for developing PARP-1 inhibitors for drug discovery and patient care. We have synthesized several derivatives of benzimidazole carboxamide as PARP-1 inhibitors, which can be (18)F-labeled easily for positron emission tomographic (PET) imaging. Of the compounds synthesized, 12 had the highest inhibition potency for PARP-1 (IC50=6.3 nM). [(18)F]12 was synthesized under conventional conditions in high specific activity with 40-50% decay-corrected yield. MicroPET studies using [(18)F]12 in MDA-MB-436 tumor-bearing mice demonstrated accumulation of [(18)F]12 in the tumor that was blocked by olaparib, suggesting that the uptake of [(18)F]12 in the tumor is specific to PARP-1 expression.

Keywords
Imaging; PARP-1; PET; Radiolabeling.
Products